Your browser doesn't support javascript.
loading
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.
Miller, Brian C; Sen, Debattama R; Al Abosy, Rose; Bi, Kevin; Virkud, Yamini V; LaFleur, Martin W; Yates, Kathleen B; Lako, Ana; Felt, Kristen; Naik, Girish S; Manos, Michael; Gjini, Evisa; Kuchroo, Juhi R; Ishizuka, Jeffrey J; Collier, Jenna L; Griffin, Gabriel K; Maleri, Seth; Comstock, Dawn E; Weiss, Sarah A; Brown, Flavian D; Panda, Arpit; Zimmer, Margaret D; Manguso, Robert T; Hodi, F Stephen; Rodig, Scott J; Sharpe, Arlene H; Haining, W Nicholas.
Afiliação
  • Miller BC; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sen DR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Al Abosy R; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Bi K; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
  • Virkud YV; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • LaFleur MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Yates KB; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Lako A; Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
  • Felt K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Naik GS; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Manos M; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gjini E; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Kuchroo JR; Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.
  • Ishizuka JJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Collier JL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Griffin GK; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.
  • Maleri S; Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Comstock DE; Division of Medical Sciences, Harvard Medical School, Boston, MA, USA.
  • Weiss SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Brown FD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Panda A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Zimmer MD; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Manguso RT; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rodig SJ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sharpe AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Haining WN; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Immunol ; 20(3): 326-336, 2019 03.
Article em En | MEDLINE | ID: mdl-30778252
ABSTRACT
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8+ tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8+ TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8+ TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8+ TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8+ T cells might be an important component of improving the response to checkpoint blockade.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Linfócitos do Interstício Tumoral / Linfócitos T CD8-Positivos / Anticorpos Bloqueadores / Receptor de Morte Celular Programada 1 Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Linfócitos do Interstício Tumoral / Linfócitos T CD8-Positivos / Anticorpos Bloqueadores / Receptor de Morte Celular Programada 1 Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article